Replies to post #229874 on Biotech Values

[Biowatch]

US_Military reduced haircut requirements to_promote_social_distancing

I assume RVNC and plastic surgeons will curtail activities that require close contact, if they haven't been told to already.

https://www.military.com/daily-news/2020/03/18/navy-eases-grooming-standards-limit-virus-exposure.html

18 Mar 2020
Military.com | By Gina Harkins
Sailors will be excused from meeting strict hair-length standards during the coronavirus crisis...

...The relaxed grooming standards are just the latest announcement to shake up routine military life for service members and their families as a result of the virus. Earlier on Wednesday, Navy leaders announced physical training tests would be temporarily halted. Troops across the military also face severe travel restrictions as a result of the virus.

[iwfal]

RVNC

Revance plans to report topline results for the ASPEN-1 cervical dystonia and Phase 2 plantar fasciitis trials in 2H of 2020 [as per prior guidance], and will provide additional updates as there is greater clarity.
...
The upper facial lines trial is fully enrolled, and all subjects have been dosed. Revance is on-track for 2Q 2020 readouts of the forehead and crow’s feet line Phase 2 studies

This seems odd to me. Eg How can you accurately assess facial lines without a really good set of pictures (well lit etc) comparable to the set initially taken.

And for cervical dystopia, patients can have twitches, which I assume are part of the critieria. But those wld be particularly hard to assess over video since much of the telecon SW is low frame rate.

All told I’d think tele-assessment wld add significant noise to the data, thus making it much more difficult to get positive results?

[DewDiligence]

RVNC Needham webcast today:

http://wsw.com/webcast/needham95/rvnc/

[DewDiligence]

RVNC—Abridged enrollment completed in upper-limb-spasticity phase-2—results early 2021:

https://investors.revance.com/news-releases/news-release-details/revance-announces-last-patient-enrolled-modified-juniper-phase-2

Revance Therapeutics…today announced a decision to complete enrollment in its JUNIPER Phase 2 trial of DaxibotulinumtoxinA for Injection for the treatment of upper limb spasticity in adults after stroke or traumatic brain injury.

Due to ongoing COVID-19 concerns related to subject enrollment and scheduling in-person study visits, the company has chosen to end screening and complete the study with 76 subjects enrolled, along with a few subjects currently being evaluated for participation in the study. The 73 subjects dosed before enrollment was paused in March due to COVID-19 will be followed for up to 36 weeks; subjects enrolled after this will be followed to Week 12. Revance now expects to announce topline data from the JUNIPER Phase 2 trial in early 2021.

RVNC announced on 3/26/20 that enrollment in the JUNIPER study had been paused due to COVID-19 (#msg-154596190).

Note: JUNIPER is entirely separate from the ASPEN-1 and ASPEN-OLS studies in cervical dystionia.